Laila Belcaid

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker.

Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker.

Journal: Clinical and experimental medicine

Published: January 16, 2026

Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023.

Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023.

Journal: Neuro-oncology practice

Published: February 07, 2025

Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases.

Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases.

Journal: Radiology

Published: November 26, 2024

Copenhagen Prospective Personalized Oncology (CoPPO)-impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting.

Copenhagen Prospective Personalized Oncology (CoPPO)-impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 15, 2024

Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials.

Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials.

Journal: NPJ precision oncology

Published: March 15, 2024

Comprehensive analysis of failure to carry out successful genomic profiling in a phase I setting.

Comprehensive analysis of failure to carry out successful genomic profiling in a phase I setting.

Journal: ESMO open

Published: January 11, 2024

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.

Journal: The journal of liquid biopsy

Published: July 24, 2023

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.

Journal: Molecular cancer

Published: July 06, 2023

Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.

Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 03, 2023

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.

Journal: BMC cancer

Published: December 22, 2022

Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.

Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 19, 2022

New pathogenic germline variants identified in mesothelioma.

New pathogenic germline variants identified in mesothelioma.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 15, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026